Yuyu Pharma, Inc. (000227.KS)
KRW 9750.0
(-0.41%)
KRW 9750.0
(-0.41%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 198.21 Billion KRW | 1.54% |
| 2022 | 195.2 Billion KRW | 1.15% |
| 2021 | 192.98 Billion KRW | 24.59% |
| 2020 | 154.9 Billion KRW | 12.48% |
| 2019 | 137.71 Billion KRW | 1.84% |
| 2018 | 135.22 Billion KRW | 11.31% |
| 2017 | 121.49 Billion KRW | 9.16% |
| 2016 | 111.29 Billion KRW | 6.68% |
| 2015 | 104.32 Billion KRW | 2.89% |
| 2014 | 101.4 Billion KRW | 5.34% |
| 2013 | 96.26 Billion KRW | 8.55% |
| 2012 | 88.67 Billion KRW | 0.2% |
| 2011 | 88.5 Billion KRW | -4.71% |
| 2010 | 92.87 Billion KRW | -3.87% |
| 2009 | 96.61 Billion KRW | -8.56% |
| 2008 | 105.66 Billion KRW | -16.72% |
| 2007 | 126.87 Billion KRW | 4.75% |
| 2006 | 121.11 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 196.71 Billion KRW | -0.76% |
| 2024 Q2 | 198.06 Billion KRW | 0.69% |
| 2023 FY | 198.21 Billion KRW | 1.54% |
| 2023 Q3 | 196.58 Billion KRW | -2.0% |
| 2023 Q2 | 200.58 Billion KRW | 2.04% |
| 2023 Q4 | 198.21 Billion KRW | 0.83% |
| 2023 Q1 | 196.57 Billion KRW | 0.7% |
| 2022 Q4 | 195.2 Billion KRW | 2.82% |
| 2022 FY | 195.2 Billion KRW | 1.15% |
| 2022 Q3 | 189.85 Billion KRW | -1.4% |
| 2022 Q2 | 192.54 Billion KRW | -1.65% |
| 2022 Q1 | 195.77 Billion KRW | 1.45% |
| 2021 FY | 192.98 Billion KRW | 24.59% |
| 2021 Q2 | 192.44 Billion KRW | 20.2% |
| 2021 Q3 | 195.64 Billion KRW | 1.66% |
| 2021 Q4 | 192.98 Billion KRW | -1.36% |
| 2021 Q1 | 160.11 Billion KRW | 3.37% |
| 2020 Q2 | 152.93 Billion KRW | 9.05% |
| 2020 FY | 154.9 Billion KRW | 12.48% |
| 2020 Q3 | 149.98 Billion KRW | -1.93% |
| 2020 Q1 | 140.24 Billion KRW | 1.84% |
| 2020 Q4 | 154.9 Billion KRW | 3.28% |
| 2019 Q4 | 137.71 Billion KRW | 3.44% |
| 2019 Q3 | 133.14 Billion KRW | -0.95% |
| 2019 FY | 137.71 Billion KRW | 1.84% |
| 2019 Q1 | 133.06 Billion KRW | -1.6% |
| 2019 Q2 | 134.42 Billion KRW | 1.02% |
| 2018 Q2 | 143.57 Billion KRW | 15.03% |
| 2018 FY | 135.22 Billion KRW | 11.31% |
| 2018 Q4 | 135.22 Billion KRW | -3.27% |
| 2018 Q3 | 139.8 Billion KRW | -2.63% |
| 2018 Q1 | 124.81 Billion KRW | 0.0% |
| 2017 FY | 121.49 Billion KRW | 9.16% |
| 2017 Q1 | 111.29 Billion KRW | -3.69% |
| 2017 Q2 | 116.02 Billion KRW | 4.25% |
| 2017 Q3 | 120.92 Billion KRW | 4.23% |
| 2016 Q4 | 115.56 Billion KRW | 7.41% |
| 2016 Q3 | 107.59 Billion KRW | 0.88% |
| 2016 Q2 | 106.66 Billion KRW | 2.24% |
| 2016 Q1 | 104.32 Billion KRW | -0.66% |
| 2016 FY | 111.29 Billion KRW | 6.68% |
| 2015 Q1 | 101.4 Billion KRW | 7.19% |
| 2015 FY | 104.32 Billion KRW | 2.89% |
| 2015 Q4 | 105.02 Billion KRW | -1.76% |
| 2015 Q3 | 106.9 Billion KRW | -2.32% |
| 2015 Q2 | 109.44 Billion KRW | 7.93% |
| 2014 Q4 | 94.59 Billion KRW | -2.09% |
| 2014 Q3 | 96.62 Billion KRW | 3.13% |
| 2014 Q2 | 93.69 Billion KRW | -2.67% |
| 2014 Q1 | 96.26 Billion KRW | 1.0% |
| 2014 FY | 101.4 Billion KRW | 5.34% |
| 2013 Q3 | 91.92 Billion KRW | 0.58% |
| 2013 Q2 | 91.39 Billion KRW | 3.06% |
| 2013 FY | 96.26 Billion KRW | 8.55% |
| 2013 Q1 | 88.67 Billion KRW | 0.0% |
| 2013 Q4 | 95.3 Billion KRW | 3.69% |
| 2012 FY | 88.67 Billion KRW | 0.2% |
| 2011 Q4 | 87.92 Billion KRW | -0.38% |
| 2011 Q2 | 94.4 Billion KRW | 1.65% |
| 2011 Q3 | 88.25 Billion KRW | -6.51% |
| 2011 Q1 | 92.87 Billion KRW | 0.89% |
| 2011 FY | 88.5 Billion KRW | -4.71% |
| 2010 Q3 | 93.31 Billion KRW | -0.9% |
| 2010 Q2 | 94.16 Billion KRW | -2.53% |
| 2010 Q1 | 96.61 Billion KRW | 7.76% |
| 2010 Q4 | 92.05 Billion KRW | -1.36% |
| 2010 FY | 92.87 Billion KRW | -3.87% |
| 2009 Q4 | 89.65 Billion KRW | -3.52% |
| 2009 Q2 | 100.2 Billion KRW | -5.17% |
| 2009 Q3 | 92.93 Billion KRW | -7.26% |
| 2009 FY | 96.61 Billion KRW | -8.56% |
| 2009 Q1 | 105.66 Billion KRW | -11.44% |
| 2008 Q3 | 122.82 Billion KRW | -1.03% |
| 2008 Q1 | 126.87 Billion KRW | -0.4% |
| 2008 FY | 105.66 Billion KRW | -16.72% |
| 2008 Q4 | 119.31 Billion KRW | -2.86% |
| 2008 Q2 | 124.1 Billion KRW | -2.18% |
| 2007 Q2 | 126.28 Billion KRW | 0.0% |
| 2007 Q4 | 127.37 Billion KRW | 1.6% |
| 2007 Q3 | 125.36 Billion KRW | -0.72% |
| 2007 FY | 126.87 Billion KRW | 4.75% |
| 2006 FY | 121.11 Billion KRW | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Dong-A Socio Holdings Co., Ltd. | 1957.1 Billion KRW | 89.872% |
| Ildong Holdings Co., Ltd. | 876.99 Billion KRW | 77.399% |
| HANDOK Inc. | 790.33 Billion KRW | 74.92% |
| Kukje Pharma Co., Ltd. | 170.61 Billion KRW | -16.173% |
| Yuhan Corporation | 2814.07 Billion KRW | 92.956% |
| Dong-A ST Co., Ltd. | 1315.21 Billion KRW | 84.929% |
| SAMSUNG PHARM. Co., LTD. | 93.47 Billion KRW | -112.041% |
| Hanmi Pharm. Co., Ltd. | 1952.03 Billion KRW | 89.846% |
| Hanall Biopharma Co.,Ltd | 239.74 Billion KRW | 17.324% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 57.728% |
| Dong Sung Bio Pharm.Co.,Ltd. | 114.97 Billion KRW | -72.4% |
| MYUNGMOON Pharm co.,Ltd | 236.54 Billion KRW | 16.206% |
| Hana Pharm Co., Ltd. | 348.38 Billion KRW | 43.105% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 0.0% |
| Ilsung Pharmaceuticals Co., Ltd. | 419.18 Billion KRW | 52.715% |
| REYON Pharmaceutical Co., Ltd. | 499.77 Billion KRW | 60.339% |
| Aprogen pharmaceuticals,Inc. | 589.39 Billion KRW | 66.37% |
| JW Holdings Corporation | 1176.26 Billion KRW | 83.149% |
| Ildong Pharmaceutical Co., Ltd. | 611.26 Billion KRW | 67.573% |
| Chong Kun Dang Pharmaceutical Corp. | 1402.42 Billion KRW | 85.866% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 69.271% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 43.381% |
| Hyundai Pharmaceutical Co., Ltd. | 154.04 Billion KRW | -28.676% |
| Samil Pharmaceutical Co.,Ltd | 370.68 Billion KRW | 46.527% |
| Jeil Pharmaceutical Co.,Ltd | 487.32 Billion KRW | 59.326% |
| Yuyu Pharma, Inc. | 198.21 Billion KRW | 0.0% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1078.06 Billion KRW | 81.614% |
| Daewoong pharmaceutical Co.,Ltd | 1770.31 Billion KRW | 88.803% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 69.271% |
| Yuhan Corporation | 2814.07 Billion KRW | 92.956% |
| Jeil Pharma Holdings Inc | 879.99 Billion KRW | 77.476% |
| Yungjin Pharm. Co., Ltd. | 226.6 Billion KRW | 12.527% |
| Suheung Co., Ltd. | 993.73 Billion KRW | 80.054% |
| JW Pharmaceutical Corporation | 645.03 Billion KRW | 69.271% |
| Samjin Pharmaceuticals Co., Ltd. | 419.9 Billion KRW | 52.795% |
| Korea United Pharm Inc. | 468.86 Billion KRW | 57.724% |
| CKD Bio Corp. | 293.78 Billion KRW | 32.531% |
| Daewon Pharmaceutical Co., Ltd. | 507.99 Billion KRW | 60.981% |
| Dongwha Pharm.Co.,Ltd | 564.97 Billion KRW | 64.916% |
| Whan In Pharm Co.,Ltd. | 401.22 Billion KRW | 50.598% |
| Shin Poong Pharm.Co.,Ltd. | 350.08 Billion KRW | 43.381% |
| Chong Kun Dang Holdings Corp. | 1456 Billion KRW | 86.386% |
| Boryung Corporation | 922.36 Billion KRW | 78.51% |
| Bukwang Pharmaceutical Co., Ltd. | 442.46 Billion KRW | 55.202% |
| Ilyang Pharmaceutical Co.,Ltd | 468.9 Billion KRW | 57.728% |
| JW Lifescience Corporation | 255.83 Billion KRW | 22.523% |